Tyr281
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr281  -  G6f (human)

Site Information
FKPEIQVyENIHLAR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450289

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 4 , 7 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 ) , mutation of modification site ( 8 ) , phospho-antibody ( 4 , 7 , 8 ) , western blotting ( 8 )
Disease tissue studied:
hepatocellular carcinoma, surrounding tissue ( 5 ) , ovarian cancer ( 2 ) , melanoma skin cancer ( 3 ) , thymic carcinoma ( 1 )
Relevant cell line - cell type - tissue:
COS (fibroblast) ( 8 ) , hepatic-'liver, para-hepatocellular carcinoma tissue' ( 5 ) , K562 (erythroid) ( 8 ) , ovary ( 2 ) , platelet-blood ( 4 , 7 ) , skin ( 3 ) , thymus ( 1 )

Upstream Regulation
Treatments:
collagen ( 7 ) , CRP ( 7 ) , vanadate ( 8 )

Downstream Regulation
Effects of modification on G6f:
molecular association, regulation ( 7 , 8 ) , phosphorylation ( 8 )
Induce interaction with:
GRB2 (human) ( 7 , 8 ) , GRB7 (human) ( 8 )

References 

1

Li Y (2011) CST Curation Set: 10459; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

2

Ren H (2010) CST Curation Set: 8826; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Tucker M (2009) CST Curation Set: 8380; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

4

Senis YA, et al. (2009) Proteomic analysis of integrin alphaIIbbeta3 outside-in signaling reveals Src-kinase-independent phosphorylation of Dok-1 and Dok-3 leading to SHIP-1 interactions. J Thromb Haemost 7, 1718-26
19682241   Curated Info

5

Gu T (2009) CST Curation Set: 7541; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Rikova K (2008) CST Curation Set: 4795; Year: 2008; Biosample/Treatment: cell line, SloanK ES 9723/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

GarcĂ­a A, et al. (2006) A global proteomics approach identifies novel phosphorylated signaling proteins in GPVI-activated platelets: involvement of G6f, a novel platelet Grb2-binding membrane adapter. Proteomics 6, 5332-43
16941570   Curated Info

8

De Vet EC, Aguado B, Campbell RD (2003) Adaptor signalling proteins Grb2 and Grb7 are recruited by human G6f, a novel member of the immunoglobulin superfamily encoded in the MHC. Biochem J 375, 207-13
12852788   Curated Info